Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Post by threefiftynineon Jun 03, 2020 2:22pm

107 Views

Post# 31107894

-----FORGET A BUYER---

Theres no way on this earth would the TSX approve a pp at .085 if a buyer was on the table. This pp is fast becoming an obstacle to the cred of this company and its ceo---and if there was a buyer it would be at .085 ---who would pay more than the valuation of the company at .085 and if they hit the phase1 goal the company would be worth over the yearly high ---such a shambles really

Bullboard Posts

Record Q3: Equinox Gold achieves commercial production at Greenstone Mine